2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

This article was originally published on this site

Jefferies is out with a prediction that biotech merger-and-acquisition (M&A) activity should pick up markedly in the second half of the yearThe investment firm notes that the SPDR S&P Biotech ETF (XBI) is down about 25% from its February highs, making purchases cheaper for larger acquirersThe second quarter was especially weak for deal volume, as …

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a subscriber? Please Login